|
1
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vokes EE: Induction chemotherapy for head
and neck cancer: Recent data. Oncologist. 15 (Suppl 3):S3–S7. 2010.
View Article : Google Scholar
|
|
3
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okano S, Yoshino T, Fujii M, Onozawa Y,
Kodaira T, Fujii H, Akimoto T, Ishikura S, Oguchi M, Zenda S, et
al: Phase II study of cetuximab plus concomitant boost radiotherapy
in Japanese patients with locally advanced squamous cell carcinoma
of the head and neck. Jpn J Clin Oncol. 43:476–482. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoshino T, Hasegawa Y, Takahashi S, Monden
N, Homma A, Okami K, Onozawa Y, Fujii M, Taguchi T, de Blas B, et
al: Platinum-based chemotherapy plus cetuximab for the first-line
treatment of Japanese patients with recurrent and/or metastatic
squamous cell carcinoma of the head and neck: Results of a phase II
trial. Jpn J Clin Oncol. 43:524–531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cohen EE, Davis DW, Karrison TG, Seiwert
TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, et al:
Erlotinib and bevacizumab in patients with recurrent or metastatic
squamous-cell carcinoma of the head and neck: A phase I/II study.
Lancet Oncol. 10:247–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Downward J, Yarden Y, Mayes E, Scrace G,
Totty N, Stockwell P, Ullrich A, Schlessinger J and Waterfield MD:
Close similarity of epidermal growth factor receptor and v-erb-B
oncogene protein sequences. Nature. 307:521–527. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ogiso H, Ishitani R, Nureki O, Fukai S,
Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M and
Yokoyama S: Crystal structure of the complex of human epidermal
growth factor and receptor extracellular domains. Cell.
110:775–787. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dokala A and Thakur SS: Extracellular
region of epidermal growth factor receptor: A potential target for
anti-EGFR drug discovery. Oncogene. 36:2337–2344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mendelsohn J: The epidermal growth factor
receptor as a target for cancer therapy. Endocr Relat Cancer.
8:3–9. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Itai S, Yamada S, Kaneko MK, Chang YW,
Harada H and Kato Y: Establishment of EMab-134, a sensitive and
specific Anti-epidermal growth factor receptor monoclonal antibody
for detecting squamous cell carcinoma cells of the oral cavity.
Monoclon Antib Immunodiagn Immunother. 36:272–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaneko MK, Yamada S, Itai S, Chang YW,
Nakamura T, Yanaka M and Kato Y: Elucidation of the critical
epitope of an anti-EGFR monoclonal antibody EMab-134. Biochem
Biophys Rep. 14:54–57. 2018.PubMed/NCBI
|
|
14
|
Fujii Y, Kaneko MK and Kato Y: MAP Tag: A
novel tagging system for protein purification and detection.
Monoclon Antib Immunodiagn Immunother. 35:293–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Itai S, Kaneko MK, Fujii Y, Yamada S,
Nakamura T, Yanaka M, Saidoh N, Handa S, Chang YW, Suzuki H, et al:
Development of EMab-51, a sensitive and specific anti-epidermal
growth factor receptor monoclonal antibody in flow Cytometry,
Western blot, and immunohistochemistry. Monoclon Antib Immunodiagn
Immunother. 36:214–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fujii Y, Kaneko M, Neyazaki M, Nogi T,
Kato Y and Takagi J: PA tag: A versatile protein tagging system
using a super high affinity antibody against a dodecapeptide
derived from human podoplanin. Protein Expr Purif. 95:240–247.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujii Y, Kaneko MK, Ogasawara S, Yamada S,
Yanaka M, Nakamura T, Saidoh N, Yoshida K, Honma R and Kato Y:
Development of RAP Tag, a novel tagging system for protein
detection and purification. Monoclon Antib Immunodiagn Immunother.
36:68–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kato Y, Kunita A, Abe S, Ogasawara S,
Fujii Y, Oki H, Fukayama M, Nishioka Y and Kaneko MK: The chimeric
antibody chLpMab-7 targeting human podoplanin suppresses pulmonary
metastasis via ADCC and CDC rather than via its neutralizing
activity. Oncotarget. 6:36003–36018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greillier L, Tomasini P and Barlesi F:
Necitumumab for non-small cell lung cancer. Expert Opin Biol Ther.
15:1231–1239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uchibori K, Inase N, Araki M, Kamada M,
Sato S, Okuno Y, Fujita N and Katayama R: Brigatinib combined with
anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated
non-small-cell lung cancer. Nat Commun. 8:147682017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kato Y, Ogasawara S, Oki H, Goichberg P,
Honma R, Fujii Y and Kaneko MK: LpMab-12 established by CasMab
technology specifically detects Sialylated O-Glycan on Thr52 of
platelet aggregation-stimulating domain of human podoplanin. PLoS
One. 11:e01529122016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abe S, Morita Y, Kaneko MK, Hanibuchi M,
Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, et al: A
novel targeting therapy of malignant mesothelioma using
anti-podoplanin antibody. J Immunol. 190:6239–6249. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abe S, Kaneko MK, Tsuchihashi Y, Izumi T,
Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, et
al: Antitumor effect of novel anti-podoplanin antibody NZ-12
against malignant pleural mesothelioma in an orthotopic xenograft
model. Cancer Sci. 107:1198–1205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kato Y, Mizuno T, Yamada S, Nakamura T,
Itai S, Yanaka M, Sano M and Kaneko MK: Establishment of P38Bf, a
Core-Fucose-deficient mouse-canine chimeric antibody against dog
podoplanin. Monoclon Antib Immunodiagn Immunother. 37:218–223.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kato Y and Kaneko MK: A cancer-specific
monoclonal antibody recognizes the aberrantly glycosylated
podoplanin. Sci Rep. 4:59242014. View Article : Google Scholar : PubMed/NCBI
|
